A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases - PubMed (original) (raw)
A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases
M Meyer et al. EMBO J. 1999.
Abstract
The different members of the vascular endothelial growth factor (VEGF) family act as key regulators of endothelial cell function controlling vasculogenesis, angiogenesis, vascular permeability and endothelial cell survival. In this study, we have functionally characterized a novel member of the VEGF family, designated VEGF-E. VEGF-E sequences are encoded by the parapoxvirus Orf virus (OV). They carry the characteristic cysteine knot motif present in all mammalian VEGFs, while forming a microheterogenic group distinct from previously described members of this family. VEGF-E was expressed as the native protein in mammalian cells or as a recombinant protein in Escherichia coli and was shown to act as a heat-stable, secreted dimer. VEGF-E and VEGF-A were found to possess similar bioactivities, i.e. both factors stimulate the release of tissue factor (TF), the proliferation, chemotaxis and sprouting of cultured vascular endothelial cells in vitro and angiogenesis in vivo. Like VEGF-A, VEGF-E was found to bind with high affinity to VEGF receptor-2 (KDR) resulting in receptor autophosphorylation and a biphasic rise in free intracellular Ca2+ concentration, whilst in contrast to VEGF-A, VEGF-E did not bind to VEGF receptor-1 (Flt-1). VEGF-E is thus a potent angiogenic factor selectively binding to VEGF receptor-2. These data strongly indicate that activation of VEGF receptor-2 alone can efficiently stimulate angiogenesis.
Similar articles
- Possible involvement of VEGF-FLT tyrosine kinase receptor system in normal and tumor angiogenesis.
Shibuya M, Seetharam L, Ishii Y, Sawano A, Gotoh N, Matsushime H, Yamaguchi S. Shibuya M, et al. Princess Takamatsu Symp. 1994;24:162-70. Princess Takamatsu Symp. 1994. PMID: 8983073 Review. - A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases.
Joukov V, Pajusola K, Kaipainen A, Chilov D, Lahtinen I, Kukk E, Saksela O, Kalkkinen N, Alitalo K. Joukov V, et al. EMBO J. 1996 Jan 15;15(2):290-98. EMBO J. 1996. PMID: 8617204 Free PMC article. - Vascular endothelial growth factor-induced migration of vascular smooth muscle cells in vitro.
Grosskreutz CL, Anand-Apte B, Dupláa C, Quinn TP, Terman BI, Zetter B, D'Amore PA. Grosskreutz CL, et al. Microvasc Res. 1999 Sep;58(2):128-36. doi: 10.1006/mvre.1999.2171. Microvasc Res. 1999. PMID: 10458928 - Molecular biology of the VEGF and the VEGF receptor family.
Clauss M. Clauss M. Semin Thromb Hemost. 2000;26(5):561-9. doi: 10.1055/s-2000-13213. Semin Thromb Hemost. 2000. PMID: 11129413 Review.
Cited by
- ORF virus causes tumor-promoting inflammation in sheep and goats.
Pintus D, Cancedda MG, Puggioni G, Scivoli R, Rocchigiani AM, Maestrale C, Coradduzza E, Bechere R, Silva-Flannery L, Bullock HA, Macciocu S, Montesu MA, Marras V, Dore S, Ritter JM, Ligios C. Pintus D, et al. Vet Pathol. 2024 Sep;61(5):803-814. doi: 10.1177/03009858241241794. Epub 2024 Apr 13. Vet Pathol. 2024. PMID: 38613413 Free PMC article. - Biology and therapeutic targeting of vascular endothelial growth factor A.
Pérez-Gutiérrez L, Ferrara N. Pérez-Gutiérrez L, et al. Nat Rev Mol Cell Biol. 2023 Nov;24(11):816-834. doi: 10.1038/s41580-023-00631-w. Epub 2023 Jul 25. Nat Rev Mol Cell Biol. 2023. PMID: 37491579 Review. - Association of Kinase-Insert-Domain-Containing Receptor Polymorphisms with Glioma Susceptibility in a Chinese Population: A Hospital-Based Case-Control Study.
Huang ZF, Zhu W, Wang C, Mo LD, Huang HL, Tong XG. Huang ZF, et al. Evid Based Complement Alternat Med. 2023 Apr 18;2023:8808422. doi: 10.1155/2023/8808422. eCollection 2023. Evid Based Complement Alternat Med. 2023. PMID: 37114147 Free PMC article. - The Clinical Impact of Vascular Endothelial Growth Factor/Receptor (VEGF/R) Inhibitors on Voice.
Ng CHL, Damrose EJ. Ng CHL, et al. Case Rep Otolaryngol. 2023 Apr 1;2023:1902876. doi: 10.1155/2023/1902876. eCollection 2023. Case Rep Otolaryngol. 2023. PMID: 37038462 Free PMC article. - Targeting tumor vasculature to improve antitumor activity of T cells armed ex vivo with T cell engaging bispecific antibody.
Park JA, Espinosa-Cotton M, Guo HF, Monette S, Cheung NV. Park JA, et al. J Immunother Cancer. 2023 Mar;11(3):e006680. doi: 10.1136/jitc-2023-006680. J Immunother Cancer. 2023. PMID: 36990507 Free PMC article.
References
- Science. 1992 Feb 21;255(5047):989-91 - PubMed
- Endocr Rev. 1992 Feb;13(1):18-32 - PubMed
- Biochem Biophys Res Commun. 1992 Sep 30;187(3):1579-86 - PubMed
- Proc Natl Acad Sci U S A. 1991 Jul 1;88(13):5819-23 - PubMed
- J Am Acad Dermatol. 1991 Oct;25(4):706-11 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous